Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, a recombinant factor IX Fc fusion protein
- 20 November 2020
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 27 (4) , E484-E486
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' OrganisationHaemophilia, 2020
- A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia BHaemophilia, 2020
- Switching to extended half‐life products in Canada – preliminary dataHaemophilia, 2017
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trialBlood, 2016
- Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection databaseHaemophilia, 2013
- Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)British Journal of Haematology, 2012
- Parallel use of by‐passing agents in haemophilia with inhibitors: a critical reviewBritish Journal of Haematology, 2011
- Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitorsHaemophilia, 2011
- Inhibitor development in haemophilia B: an orphan disease in need of attentionBritish Journal of Haematology, 2007